MEBGEN™ RASKET KIT RAS mutation detection kit
Colorectal cancer (CRC)
Colorectal cancer occurs with greater incidence and higher mortality. GLOBOCAN data reports that 1.2M people are diagnosed (370K in EU and 160K in US) with colorectal cancer and 600K people die (160K in EU and 55K in US) from the disease.
Chemotherapies for metastatic CRC (mCRC) have made spectacular progress. 5-fluorourachil (5-FU), Irinotecan (CPT-11), Oxaliplatin (L-PHP), and their combination have increased the survival rates in patients with mCRC. Meanwhile, molecularly targeted agents have become a major focus on clinical research since the first agents (cetuximab and bevacizumab) were approved by FDA and EMA in 2004. Nowadays, the concept of "personalized medicine" and/or "companion diagnostics" are gaining more interest. Many clinical studies on molecular markers such as KRAS and NRAS have established their effects to increase the response rate to anti-EGFR therapeutic antibodies through selecting colorectal cancer patients to be treated with the agents. This can result in both improvement of patients’ quality of life (QOL) and reduction of the economical burden.